Literature DB >> 1737674

Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations.

R T Johnston1, D P de Bono, C R Nyman.   

Abstract

Angiotensin-converting-enzyme inhibitors are frequently used in conjunction with diuretics in the treatment of congestive cardiac failure. We report two cases in which use of a proprietary combination diuretic containing a loop diuretic and potassium sparing agent with an angiotensin converting enzyme inhibitor was associated with hyperkalaemic cardiac arrest. Successful resuscitation from the arrest permitted elucidation of its mechanism. We believe that this outcome has not previously been reported, and emphasise the importance of electrolyte monitoring in patients receiving angiotensin converting enzyme inhibitors particularly if prescribed in addition to fixed combination proprietary diuretics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737674     DOI: 10.1016/0167-5273(92)90159-z

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.

Authors:  Eike Wrenger; Regina Müller; Michael Moesenthin; Tobias Welte; Jürgen C Frölich; Klaus H Neumann
Journal:  BMJ       Date:  2003-07-19

Review 2.  Sudden cardiac death in CKD patients.

Authors:  Beata Franczyk-Skóra; Anna Gluba-Brzózka; Jerzy Krzysztof Wranicz; Maciej Banach; Robert Olszewski; Jacek Rysz
Journal:  Int Urol Nephrol       Date:  2015-05-12       Impact factor: 2.370

3.  Identification of severe potential drug-drug interactions using an Italian general-practitioner database.

Authors:  L Magro; A Conforti; F Del Zotti; R Leone; M L Iorio; I Meneghelli; D Massignani; E Visonà; U Moretti
Journal:  Eur J Clin Pharmacol       Date:  2007-11-09       Impact factor: 2.953

4.  [Drug interactions in clinical practice. A pilot project for quality assurance in prescribing].

Authors:  U Geppert; W Beindl; T Hawranek; H Hintner
Journal:  Hautarzt       Date:  2002-12-20       Impact factor: 0.751

5.  Potential drug-drug interactions in the medication of medical patients at hospital discharge.

Authors:  Sabin S Egger; Jürgen Drewe; Raymond G Schlienger
Journal:  Eur J Clin Pharmacol       Date:  2003-02-21       Impact factor: 2.953

6.  Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

Authors:  Yshai Yavin; Traci A Mansfield; Agata Ptaszynska; Kristina Johnsson; Shamik Parikh; Eva Johnsson
Journal:  Diabetes Ther       Date:  2016-01-12       Impact factor: 2.945

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.